189 related articles for article (PubMed ID: 33739786)
21. Serous endometrial intraepithelial carcinoma (SEIC): Current clinical practice in The Netherlands.
Slaager C; Hofhuis W; Hoogduin K; Ewing-Graham P; van Beekhuizen H
Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():25-29. PubMed ID: 34416579
[TBL] [Abstract][Full Text] [Related]
22. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Klc TR; Wu S; Wilhite AM; Jones NL; Powell MA; Olawaiye A; Girda E; Brown J; Puechl A; Ali-Fehmi R; Winer IS; Herzog TJ; Korn WM; Erickson BK
Gynecol Oncol; 2022 Nov; 167(2):289-294. PubMed ID: 36114027
[TBL] [Abstract][Full Text] [Related]
23. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
Lateef F; Jamal S; Nasir S
J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N; Hui P
Arch Pathol Lab Med; 2022 Jun; 146(5):0. PubMed ID: 35687792
[TBL] [Abstract][Full Text] [Related]
25. Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma.
Kommoss F; Faruqi A; Gilks CB; Lamshang Leen S; Singh N; Wilkinson N; McCluggage WG
Am J Surg Pathol; 2017 Feb; 41(2):161-170. PubMed ID: 27776011
[TBL] [Abstract][Full Text] [Related]
26. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
[TBL] [Abstract][Full Text] [Related]
27. A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?
Hou JY; McAndrew TC; Goldberg GL; Whitney K; Shahabi S
Reprod Sci; 2014 Apr; 21(4):532-7. PubMed ID: 24023030
[TBL] [Abstract][Full Text] [Related]
28. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
29. Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions.
Furuya M; Sato T; Tanaka R; Yamamoto M; Yokota NR; Miyagi E
Diagn Pathol; 2016 Nov; 11(1):130. PubMed ID: 27842566
[TBL] [Abstract][Full Text] [Related]
30. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
31. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
32. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
33. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
Buza N; English DP; Santin AD; Hui P
Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
[TBL] [Abstract][Full Text] [Related]
34. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
[TBL] [Abstract][Full Text] [Related]
35. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
Chao WR; Lee MY; Lin WL; Koo CL; Sheu GT; Han CP
Am J Surg Pathol; 2014 Sep; 38(9):1227-34. PubMed ID: 25133707
[TBL] [Abstract][Full Text] [Related]
36. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
38. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
[TBL] [Abstract][Full Text] [Related]
39. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
40. Papillary syncytial metaplasia associated with endometrial breakdown exhibits an immunophenotype that overlaps with uterine serous carcinoma.
McCluggage WG; McBride HA
Int J Gynecol Pathol; 2012 May; 31(3):206-10. PubMed ID: 22498936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
